⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1434293 | 0.72 | — | — | |
| SCHEMBL2640146 | 0.67 | — | — | |
| SCHEMBL1190870 | 0.61 | — | — | |
| SCHEMBL2554291 | 0.57 | — | — | |
| SCHEMBL7167813 | 0.55 | — | — | |
| SCHEMBL10644791 | 0.55 | — | — | |
| SCHEMBL8938 | 0.55 | — | — | |
| SCHEMBL13255034 | 0.54 | — | — | |
| SCHEMBL39285 | 0.54 | — | — | |
| SCHEMBL20587826 | 0.52 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183261-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | ABBVIE INC (US) | 2023-06-15 | — | — | US | claimed |
| EP-3988555-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2022-04-27 | — | — | EP | claimed |
| US-20220048884-A1 | NRF2 ACTIVATOR | BIOGEN MA INC. | 2022-02-17 | — | — | US | claimed |
| EP-3319606-B1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD (GB) | 2020-12-09 | — | — | EP | claimed |
| CN-111818917-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2020-10-23 | — | — | CN | claimed |
| US-20200325153-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | ABBVIE INC (US) | 2020-10-15 | — | — | US | claimed |
| EP-3371191-B1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME (US) | 2020-08-26 | — | — | EP | claimed |
| EP-3226688-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME (US) | 2020-07-01 | — | — | EP | claimed |
| EP-3226690-B1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME (US) | 2020-05-20 | — | — | EP | claimed |
| EP-3652184-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-05-20 | — | — | EP | claimed |
| US-9675592-B2 | Methods and compositions for bacteria infections | THE UNIVERSITY OF CHICAGO (US) | 2017-06-13 | — | — | US | claimed |
| WO-2017074914-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | claimed |
| WO-2017007700-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2017-01-12 | — | — | WO | claimed |
| WO-2016160938-A1 | N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS | ABBVIE INC. (US) | 2016-10-06 | — | — | WO | claimed |
| WO-2016089797-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | claimed |
| WO-2016089833-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | claimed |
| WO-2016089830-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | claimed |
| US-20160120852-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF ILLINOIS (US) | 2016-05-05 | — | — | US | claimed |
| EP-2969003-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | The University of Chicago (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014144710-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2014-09-18 | — | — | WO | claimed |